Research Article
Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study
Figure 2
Kaplan-Meier survival for progression-free survival (PFS) according to the treatment approach. Patients who received both systemic and locoregional therapies had significantly longer PFS than those who received systemic therapy alone. The median PFS was 16.3, 14.0, and 9.3 months in the ST to LRT, LRT to ST, and ST alone groups, respectively. ST to LRT: systemic therapy followed by locoregional therapy; LRT to ST: locoregional therapy followed by systemic therapy; ST: systemic therapy.